Monday, October 02, 2023
RaySearch Labs AB (publ) is excited to announce the expansion of its partnership with P-Cure, with a focus on enhancing the operational efficiency of P-Cure's proton therapy system through the seamless integration of RaySearch's RayStation®* and RayCare®* systems.
This extended collaboration will enable users of the P-Cure proton therapy system to enjoy the benefits of a fully integrated environment with RayStation and RayCare. Notably, the P-Cure system, recognized for its gantry-less seated proton technology designed to fit within linac vaults, has recently received clearance from the FDA. It is currently in clinical use at the Hadassah Medical Center in Jerusalem, the Middle East's exclusive proton facility, where it is employed in the treatment of conditions such as CNS, head and neck, thoracic, and pancreatic malignancies.
This partnership represents a natural progression of the existing relationship between the two companies, which has already resulted in the successful integration of RayStation into a study conducted at the P-Cure clinical development center, operated by the Hadassah Medical Center.
The collaboration will provide users of the P-Cure proton therapy system with access to RayCare's automation and workflow support, as well as the advanced adaptive radiation therapy features found within the RaySearch systems.
Dr. Michael Marash, CEO of P-Cure, conveys his optimism, stating, "Our collaboration with RaySearch, a worldwide frontrunner in treatment planning, will have a substantial impact on our pioneering endeavors to extend the reach of proton therapy and benefit a broader global patient population. I'm pleased that we're elevating our partnership to the next level, as I see substantial potential in the synergy between our technologies."
Johan Löf, founder and CEO of RaySearch, shares Dr. Marash's enthusiasm, stating, "We take great pride in collaborating with a company that is driving innovation in proton therapy. P-Cure's pioneering work in upright radiation therapy and its ability to provide a proton system within a standard linac room hold immense promise for the expansion of proton therapy."